InsidersTradesSigma
Track the Xeris Biopharma Holdings, Inc. share price and the full insider trade history of the company, a listed issuer based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Xeris Biopharma Holdings, Inc. has recorded 148 public disclosures. Market capitalisation: €2.3bn. The latest transaction was filed on 1 September 2026 (Cession). Among the most active insiders: Hecht Beth. Every trade is accessible without an account.
148
Insider Decl.
n/a
Thresholds
€966,723
18 ops.
Buy Volume
€4m
23 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Xeris Biopharma Holdings, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$62.05.
31Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 23,330 of 29,064 companies
30.4
score / 100
Value24
Quality37
FCF yld-3.8%
Earn yld-4.8%
EV/EBITDA·
ROE-40%
Gross mgn99%
Net mgn-44%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 1 September 2026
Declarations148 total
16,666 shares@ US$8.4864Common StockSEC:0001652410-26-000018:0
15,000 shares@ US$8.4872Common StockSEC:0002031695-26-000011:0
21,918 shares@ US$8.080.0076% mcap17.2% of flowCommon StockSEC:0001867096-26-000069:0
36,645 shares@ US$8.080.013% mcap20.9% of flowCommon StockSEC:0001867096-26-000073:0
5,000 shares@ US$8.500.0018% mcap3.4% of flowCommon StockSEC:0001875714-26-000009:0
15,000 shares@ US$8.0160.0052% mcap14.1% of flowCommon StockSEC:0001867096-26-000059:0
16,666 shares@ US$8.01350.0058% mcap10.0% of flowCommon StockSEC:0001652410-26-000016:0
27,600 shares@ US$8.370.010% mcap61.6% of flowCommonSEC144:0001950047-26-006941
17,400 shares@ US$8.500.0064% mcap13.0% of flowCommon StockSEC:0001875714-26-000007:0
27,600 shares@ US$8.52450.010% mcap20.6% of flowCommon StockSEC:0001875714-26-000007:1
17,400 shares@ US$8.280.0063% mcap38.4% of flowCommonSEC144:0001950047-26-006884
49,998 shares@ US$7.920.017% mcap100.0% of flowCommonSEC144:0001950047-26-006741
120,000 shares@ US$7.920.042% mcap100.0% of flowCommonSEC144:0001950047-26-006705
24,193 shares0Common StockSEC:0001635065-26-000002:1
16,000 shares@ US$6.09420.0042% mcap74.1% of flowCommon StockSEC:0001635065-26-000002:0
24,193 shares0Common StockSEC:0001916987-26-000004:0
16,000 shares@ US$5.890.0040% mcap100.0% of flowCommonSEC144:0001950047-26-005661
20,000 shares@ US$5.890.0050% mcap100.0% of flowCommonSEC144:0001950047-26-005664
15,000 shares@ US$5.890.0038% mcap100.0% of flowCommonSEC144:0001950047-26-005663
15,500 shares@ US$6.000.0040% mcap100.0% of flowCOMMONSEC144:0001950047-26-005565
16,667 shares@ US$6.22820.0044% mcap15.2% of flowCommon StockSEC:0001652410-26-000010:0
16,667 shares@ US$5.991412.9% of flowCommon StockSEC:0001652410-26-000008:0
10,834 shares@ US$5.5414100.0% of flowCommon StockSEC:0001916987-26-000002:0
48,894 shares@ US$4.0932.9% of flowCommon StockSEC:0002031695-26-000006:0
27,891 shares@ US$4.099.3% of flowCommon StockSEC:0001875714-26-000004:0
25 of 148 declarations
关于 Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc. 是一家总部位于美国的生物制药公司，在美国纳斯达克股票市场上市，其主要办事处设在伊利诺伊州芝加哥。从股票研究的角度来看，Xeris 最好被理解为一个商业化阶段的专业制药平台，而非纯粹的早期生物技术公司。该公司专注于开发、制造和商业化差异化疗法，并由专有制剂技术提供支持，旨在提高注射药物的可用性。其平台 XeriSol/XeriJect 旨在为选定的化合物提供便捷的递送形式，这在利基内分泌学和罕见病市场中具有战略重要性。（[xerispharma.com](https://www.xerispharma.com/investor-relations/?utm_source=openai)) 该公司的起源与美国专业生物制药创新的更广泛浪潮相关，其目前的形态反映了内部产品开发和企业扩张。其发展的一个关键步骤是收购 Strongbridge，这扩大了 Xeris 的商业足迹，并加强了其在专业内分泌和罕见病治疗领域的影响力。如今，该业务围绕三个主要的商业特许经营权组织：Gvoke，一种用于严重低血糖的即用型胰高血糖素；Recorlev（左旋酮康唑），适用于手术不可行或未能治愈的成人库欣综合征内源性高皮质醇症；以及 Keveyis（二氯苯酰胺），用于治疗原发性周期性麻痹。Xeris 还通过合作安排在选定的非美国市场商业化 Ogluo。（[xerispharma.com](https://www.xerispharma.com/products?mobile=1&utm_source=openai)) 在竞争方面，Xeris 占据了一个专注但有吸引力的利基市场。其产品组合针对明确的临床需求，从而形成了重要的监管和商业进入壁垒。Gvoke 受益于紧急胰高血糖素类别的需求，而 Recorlev 最近一直是突出的增长动力，这得益于接受治疗的患者数量不断增加。Keveyis 是一种更成熟的资产，贡献了更稳定的收入基础，尽管增长较慢。因此，Xeris 具有结合了专业制药执行、罕见病风险敞口和商业增长杠杆的特点。（[xerispharma.com](https://xerispharma.com/news-releases/news-release-details/xeris-biopharma-posts-record-financial-results-third-quarter?utm_source=openai)) 从地理上看，该公司仍然高度以美国为中心，其核心运营和商业基础设施位于美国，同时通过 Ogluo 在欧洲和其他覆盖地区保持有限的国际影响力。最近的发展在运营方面尤其积极：在 2026 年，Xeris 报告了 2025 年全年创纪录的业绩，总收入为 $292 million，并提供了 2026 年 $375 million 至 $390 million 的收入指引。该公司还在 2026 年初宣布了一项与 Recorlev 相关的专利侵权诉讼，这提醒人们排他性保护对于专业制药公司而言是一个重要的战略问题。（[ir.xerispharma.com](https://ir.xerispharma.com/news-releases/news-release-details/xeris-biopharma-reports-record-performance-fourth-quarter-and?utm_source=openai))
